广康生化
(300804)
| 流通市值：14.61亿 | | | 总市值：39.31亿 |
| 流通股本：2750.00万 | | | 总股本：7400.00万 |
| 报告期 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 187,242,875.58 | 723,480,846.94 | 484,361,918.38 | 317,747,312.01 |
| 营业收入 | 187,242,875.58 | 723,480,846.94 | 484,361,918.38 | 317,747,312.01 |
| 二、营业总成本 | 172,515,413.01 | 701,124,233 | 468,169,647.03 | 302,191,674.57 |
| 营业成本 | 143,417,378.71 | 573,312,146.13 | 374,610,885.23 | 245,453,738.54 |
| 税金及附加 | 480,759 | 1,958,832.25 | 1,389,432.02 | 944,940 |
| 销售费用 | 3,237,565.46 | 13,790,831.47 | 8,363,405.86 | 5,791,716.22 |
| 管理费用 | 14,238,946.4 | 62,909,202.42 | 47,692,670.55 | 31,547,257.02 |
| 研发费用 | 7,635,984.13 | 38,829,391.03 | 27,678,651.99 | 14,935,619.12 |
| 财务费用 | 3,504,779.31 | 10,323,829.7 | 8,434,601.38 | 3,518,403.67 |
| 其中:利息费用 | 2,636,272.82 | 9,475,419.5 | 7,085,608.43 | - |
| 其中:利息收入 | 28,312.01 | 2,078,234.04 | 1,976,419.94 | - |
| 加:公允价值变动收益 | - | 295,332.05 | - | - |
| 加:投资收益 | 2,402,417.9 | 9,382,830.52 | 5,119,688.58 | 3,286,359.03 |
| 资产处置收益 | -15,128.49 | - | 0 | - |
| 资产减值损失(新) | - | -210,976.17 | - | - |
| 信用减值损失(新) | 650,232.99 | -3,664,074.07 | -4,567,319.12 | -4,920,255.75 |
| 其他收益 | 317,512.49 | 1,324,480.88 | 939,529.21 | 468,888.78 |
| 营业利润平衡项目 | 0 | 0 | 0 | 0 |
| 四、营业利润 | 18,082,497.46 | 29,484,207.15 | 17,684,170.02 | 14,390,629.5 |
| 加:营业外收入 | 70,059.25 | 12,666,004.2 | 12,095,203.1 | 12,095,203.1 |
| 减:营业外支出 | 82,785.86 | 7,588,902.79 | 4,409,103.81 | 1,147,209.95 |
| 利润总额平衡项目 | 0 | 0 | 0 | 0 |
| 五、利润总额 | 18,069,770.85 | 34,561,308.56 | 25,370,269.31 | 25,338,622.65 |
| 减:所得税费用 | 1,062,344.48 | 315,699.06 | 1,947,388.68 | 3,550,905.57 |
| 六、净利润 | 17,007,426.37 | 34,245,609.5 | 23,422,880.63 | 21,787,717.08 |
| 持续经营净利润 | 17,007,426.37 | 34,245,609.5 | 23,422,880.63 | 21,787,717.08 |
| 归属于母公司股东的净利润 | 17,109,527.99 | 34,681,288.66 | 23,691,057.28 | 21,959,087.13 |
| 少数股东损益 | -102,101.62 | -435,679.16 | -268,176.65 | -171,370.05 |
| (一)基本每股收益 | 0.23 | 0.47 | 0.32 | 0.3 |
| (二)稀释每股收益 | 0.23 | 0.47 | 0.32 | 0.3 |
| 九、综合收益总额 | 17,007,426.37 | 34,245,609.5 | 23,422,880.63 | 21,787,717.08 |
| 归属于母公司股东的综合收益总额 | 17,109,527.99 | 34,681,288.66 | 23,691,057.28 | 21,959,087.13 |
| 归属于少数股东的综合收益总额 | -102,101.62 | -435,679.16 | -268,176.65 | -171,370.05 |
| 公告日期 | 2025-04-18 | 2025-04-18 | 2024-10-25 | 2024-08-29 |
| 审计意见(境内) | | 标准无保留意见 | | |